Skip to Content

Entyvio Approval History

Entyvio (vedolizumab) is an integrin receptor antagonist for the treatment of Crohn's disease and ulcerative colitis.

Development History and FDA Approval Process for Entyvio

May 20, 2014Approval FDA Approves Entyvio (vedolizumab) to treat Ulcerative Colitis and Crohn's Disease
Dec  9, 2013FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Sep  4, 2013Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
Aug 21, 2013Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Jun 21, 2013Takeda Submits BLA for Vedolizumab for Moderately to Severely Active Crohn's Disease and Ulcerative Colitis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.